RCM
NPCE icon

Revelation Capital Management’s Neuropace NPCE Stock Holding History

Revelation Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$161K Sell
42,972
-205,155
-83% -$989K 3.78% 3
2022
Q2 		$1.23M Sell
248,127
-132,578
-35% -$876K 17.38% 2
2022
Q1 		$3.13M Sell
380,705
-285,835
-43% -$2.47M 11.43% 3
2021
Q4 		$6.72M Buy
+666,540
New +$8.66M 6.48% 3

Other funds holding NPCE

KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Revelation Capital Management's NPCE Position: Q3 2022 in Review

Revelation Capital Management reduced its Neuropace (NPCE) stake by 83% in Q3 2022, selling an estimated $989K and leaving 42,972 shares worth $161K. The position accounts for 3.78% of the portfolio, ranked #3.

Revelation Capital Management first reported a position in NPCE in Q4 2021 and has held it in 4 quarters since. The position peaked at $6.72M in Q4 2021. 28 funds tracked by Wall St. Rank hold NPCE as of Q3 2022.

  • Revelation Capital Management held 42,972 shares of Neuropace worth $161K as of Q3 2022.
  • Revelation Capital Management sold 205,155 Neuropace shares in Q3 2022, an estimated $989K.
  • Neuropace made up 3.78% of Revelation Capital Management's portfolio in Q3 2022, its #3 holding.
  • Revelation Capital Management first reported a position in Neuropace in Q4 2021 and has held it in 4 quarters since.
  • Revelation Capital Management's Neuropace position peaked at $6.72M in Q4 2021.
  • 28 funds tracked by Wall St. Rank held Neuropace as of Q3 2022.

Based on Revelation Capital Management's 13F filing for Q3 2022, filed 7 Nov 2022.